279,944 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Purchased by Twinbeech Capital LP

Twinbeech Capital LP bought a new position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 279,944 shares of the company's stock, valued at approximately $22,916,000. Twinbeech Capital LP owned about 0.22% of Vaxcyte as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Wells Fargo & Company MN raised its holdings in shares of Vaxcyte by 53.7% during the fourth quarter. Wells Fargo & Company MN now owns 72,275 shares of the company's stock valued at $5,916,000 after buying an additional 25,257 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Vaxcyte by 23.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,428 shares of the company's stock valued at $2,163,000 after buying an additional 4,962 shares during the last quarter. TimesSquare Capital Management LLC raised its holdings in shares of Vaxcyte by 53.7% during the fourth quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company's stock valued at $33,860,000 after buying an additional 144,516 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Vaxcyte by 70.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 593,523 shares of the company's stock valued at $49,418,000 after buying an additional 246,049 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its holdings in shares of Vaxcyte by 188.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after buying an additional 260 shares during the last quarter. Institutional investors own 96.78% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on PCVX. Guggenheim reiterated a "buy" rating and set a $160.00 price objective on shares of Vaxcyte in a research note on Wednesday, March 12th. Evercore ISI upgraded shares of Vaxcyte to a "strong-buy" rating in a research note on Monday, March 31st. Cantor Fitzgerald began coverage on shares of Vaxcyte in a research note on Tuesday, April 22nd. They set an "overweight" rating on the stock. Needham & Company LLC reiterated a "buy" rating and set a $90.00 price objective on shares of Vaxcyte in a research note on Tuesday, April 8th. Finally, Bank of America lowered their price objective on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Vaxcyte presently has a consensus rating of "Buy" and an average price target of $136.50.

Vaxcyte Stock Up 3.1%

Vaxcyte stock opened at $31.85 on Monday. The company's fifty day simple moving average is $42.56 and its 200-day simple moving average is $71.47. Vaxcyte, Inc. has a 12 month low of $27.66 and a 12 month high of $121.06. The stock has a market cap of $4.11 billion, a P/E ratio of -6.92 and a beta of 1.27.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter last year, the firm posted ($0.85) EPS. On average, equities research analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Insider Activity at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the completion of the transaction, the chief operating officer now owns 154,931 shares of the company's stock, valued at $11,351,794.37. The trade was a 4.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 3.10% of the stock is owned by company insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

Want to see what other hedge funds are holding PCVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxcyte, Inc. (NASDAQ:PCVX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.